Compare GSK plc (GSK) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Nuscale Power Corporation — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Nuscale Power Corporation trades at $7.21 (market cap $3.00B). The key difference: GSK plc is far larger — about 30.6× Nuscale Power Corporation's market cap, and GSK plc pays a 3.9% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Nuscale Power Corporation for 29 Days on average.
| GSK | SMR | |
|---|---|---|
Market Cap | $91.88B | $3.00B |
Volume | 7,730,529 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $61.18 | $53.43 |
52-Week Low | $43.24 | $7.32 |
Typical Hold Time | 93 Days | 29 Days |
Enterprise Value | $111.88B | $1.93B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
SMR trades at $7.145, down 6.84% on the day, reflecting ongoing investor concerns. The stock is technically bearish with moving averages signaling a downtrend, while fundamentals show severe losses with a net income margin of -3,888.7% in 2026 and negative cash flow from operations. Recent news highlights a Pomerantz law firm investigation into the company, adding to headwinds despite some analyst optimism.
The outlook remains high-risk; while 50% of analysts rate it a buy with a $11.25 consensus target, persistent losses, cash burn, and competitive pressures in the nuclear SMR space pose significant challenges. Upside depends on successful commercialization, but current financials and sentiment suggest caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
